| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Serotonin | 6 | 2019 | 137 | 2.95 | Why? |
| Extracorporeal Membrane Oxygenation | 17 | 2021 | 5002 | 1.72 | Why? |
| Myocardial Reperfusion Injury | 3 | 2019 | 129 | 1.54 | Why? |
| Blood Platelets | 8 | 2021 | 1704 | 1.47 | Why? |
| Rivaroxaban | 2 | 2019 | 467 | 1.15 | Why? |
| Platelet Aggregation Inhibitors | 5 | 2020 | 1671 | 0.85 | Why? |
| Esophageal Fistula | 1 | 2018 | 11 | 0.77 | Why? |
| Autocrine Communication | 1 | 2018 | 14 | 0.76 | Why? |
| Bronchial Fistula | 1 | 2018 | 28 | 0.74 | Why? |
| Cell-Free Nucleic Acids | 1 | 2021 | 271 | 0.71 | Why? |
| Paracrine Communication | 1 | 2018 | 73 | 0.70 | Why? |
| Hemoperfusion | 1 | 2021 | 260 | 0.68 | Why? |
| Atherosclerosis | 2 | 2018 | 768 | 0.64 | Why? |
| Peripheral Arterial Disease | 2 | 2019 | 471 | 0.63 | Why? |
| Thrombosis | 6 | 2021 | 7504 | 0.61 | Why? |
| HSP70 Heat-Shock Proteins | 1 | 2016 | 113 | 0.59 | Why? |
| Anticoagulants | 5 | 2019 | 9563 | 0.57 | Why? |
| Atrial Fibrillation | 2 | 2019 | 2320 | 0.54 | Why? |
| Social Justice | 1 | 2020 | 706 | 0.48 | Why? |
| Anemia | 1 | 2019 | 789 | 0.48 | Why? |
| Fibrinolytic Agents | 3 | 2019 | 1702 | 0.47 | Why? |
| Adsorption | 3 | 2021 | 261 | 0.46 | Why? |
| Pulmonary Embolism | 6 | 2020 | 4775 | 0.45 | Why? |
| Thrombolytic Therapy | 2 | 2019 | 2218 | 0.41 | Why? |
| Platelet Activation | 4 | 2019 | 660 | 0.39 | Why? |
| Shock, Cardiogenic | 4 | 2020 | 700 | 0.38 | Why? |
| Cytokines | 7 | 2021 | 15010 | 0.37 | Why? |
| Hemostasis | 2 | 2018 | 811 | 0.37 | Why? |
| Killer Cells, Natural | 1 | 2019 | 2093 | 0.37 | Why? |
| High-Temperature Requirement A Serine Peptidase 2 | 2 | 2017 | 3 | 0.36 | Why? |
| Thrombectomy | 1 | 2019 | 2272 | 0.34 | Why? |
| Apoptosis | 3 | 2017 | 2335 | 0.34 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.30 | Why? |
| Reperfusion Injury | 2 | 2017 | 178 | 0.30 | Why? |
| Percutaneous Coronary Intervention | 5 | 2018 | 3646 | 0.27 | Why? |
| Tryptophan Hydroxylase | 2 | 2013 | 7 | 0.26 | Why? |
| B-Lymphocytes | 1 | 2019 | 4418 | 0.26 | Why? |
| Myocardial Infarction | 6 | 2018 | 3361 | 0.26 | Why? |
| Immunity, Innate | 2 | 2019 | 6570 | 0.26 | Why? |
| Pulmonary Artery | 2 | 2020 | 803 | 0.26 | Why? |
| Neutrophils | 3 | 2019 | 5476 | 0.24 | Why? |
| Myocytes, Cardiac | 3 | 2017 | 804 | 0.24 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.24 | Why? |
| Hemorrhage | 3 | 2019 | 3013 | 0.23 | Why? |
| Tissue Plasminogen Activator | 2 | 2019 | 778 | 0.23 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.22 | Why? |
| MicroRNAs | 3 | 2018 | 1787 | 0.21 | Why? |
| Interleukin-6 | 5 | 2021 | 7522 | 0.21 | Why? |
| Computed Tomography Angiography | 2 | 2020 | 2153 | 0.21 | Why? |
| Humans | 63 | 2021 | 930598 | 0.21 | Why? |
| Aldosterone | 1 | 2021 | 155 | 0.20 | Why? |
| Platelet Membrane Glycoproteins | 1 | 2019 | 42 | 0.20 | Why? |
| Receptors, Complement | 1 | 2018 | 15 | 0.19 | Why? |
| Barotrauma | 1 | 2020 | 97 | 0.19 | Why? |
| Somalia | 1 | 2018 | 62 | 0.19 | Why? |
| Platelet Function Tests | 1 | 2020 | 231 | 0.19 | Why? |
| Germany | 8 | 2021 | 9196 | 0.19 | Why? |
| Mediastinitis | 1 | 2018 | 37 | 0.18 | Why? |
| Potassium | 1 | 2021 | 325 | 0.18 | Why? |
| Isoflurane | 1 | 2018 | 38 | 0.18 | Why? |
| ST Elevation Myocardial Infarction | 4 | 2018 | 3051 | 0.18 | Why? |
| Muscle Fatigue | 1 | 2017 | 25 | 0.17 | Why? |
| Mitochondria, Heart | 1 | 2017 | 37 | 0.17 | Why? |
| Platelet Factor 4 | 1 | 2021 | 385 | 0.17 | Why? |
| Stroke | 2 | 2018 | 8839 | 0.17 | Why? |
| Raynaud Disease | 1 | 2018 | 86 | 0.17 | Why? |
| Circulating MicroRNA | 1 | 2018 | 123 | 0.17 | Why? |
| Vitamin K | 1 | 2019 | 263 | 0.17 | Why? |
| Epinephrine | 1 | 2019 | 323 | 0.17 | Why? |
| Lipoproteins, HDL | 1 | 2018 | 154 | 0.17 | Why? |
| Compassion Fatigue | 1 | 2021 | 228 | 0.16 | Why? |
| Cell Communication | 1 | 2019 | 396 | 0.16 | Why? |
| Ticlopidine | 1 | 2018 | 193 | 0.16 | Why? |
| Hemodiafiltration | 1 | 2017 | 65 | 0.16 | Why? |
| Albumins | 1 | 2018 | 324 | 0.16 | Why? |
| Fractional Flow Reserve, Myocardial | 1 | 2018 | 173 | 0.16 | Why? |
| Respiratory Muscles | 1 | 2017 | 116 | 0.16 | Why? |
| Neutrophil Activation | 1 | 2019 | 510 | 0.15 | Why? |
| Dabigatran | 1 | 2017 | 204 | 0.15 | Why? |
| Transportation of Patients | 1 | 2021 | 494 | 0.15 | Why? |
| Hypothermia, Induced | 1 | 2018 | 176 | 0.15 | Why? |
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 291 | 0.15 | Why? |
| Propofol | 1 | 2018 | 172 | 0.15 | Why? |
| CTLA-4 Antigen | 1 | 2017 | 282 | 0.15 | Why? |
| Abatacept | 1 | 2017 | 192 | 0.15 | Why? |
| Proton Pump Inhibitors | 1 | 2020 | 377 | 0.15 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.14 | Why? |
| Angiotensin II | 1 | 2021 | 601 | 0.14 | Why? |
| Antibodies | 1 | 2021 | 846 | 0.14 | Why? |
| Psychosocial Support Systems | 1 | 2021 | 710 | 0.14 | Why? |
| Mice, Knockout | 3 | 2018 | 1815 | 0.14 | Why? |
| Factor Xa Inhibitors | 1 | 2019 | 490 | 0.14 | Why? |
| Mobile Health Units | 1 | 2021 | 741 | 0.13 | Why? |
| Leukocyte Rolling | 1 | 2012 | 7 | 0.13 | Why? |
| Fluid Therapy | 1 | 2018 | 628 | 0.13 | Why? |
| Weibel-Palade Bodies | 1 | 2012 | 9 | 0.13 | Why? |
| L-Selectin | 1 | 2012 | 42 | 0.13 | Why? |
| Chemotaxis | 1 | 2012 | 67 | 0.13 | Why? |
| Observational Studies as Topic | 1 | 2021 | 1887 | 0.13 | Why? |
| Oligopeptides | 1 | 2017 | 576 | 0.13 | Why? |
| Models, Immunological | 1 | 2019 | 727 | 0.13 | Why? |
| Male | 34 | 2021 | 367725 | 0.13 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 645 | 0.12 | Why? |
| Reactive Oxygen Species | 1 | 2019 | 1136 | 0.12 | Why? |
| Cerebral Hemorrhage | 1 | 2021 | 820 | 0.12 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.12 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.12 | Why? |
| Immunomodulation | 2 | 2019 | 1472 | 0.12 | Why? |
| Histamine | 1 | 2012 | 61 | 0.12 | Why? |
| Fluoxetine | 1 | 2012 | 77 | 0.12 | Why? |
| Coronary Disease | 1 | 2018 | 645 | 0.12 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.12 | Why? |
| Gait | 1 | 2013 | 137 | 0.12 | Why? |
| Molecular Targeted Therapy | 2 | 2018 | 1579 | 0.12 | Why? |
| Hypnotics and Sedatives | 1 | 2018 | 624 | 0.12 | Why? |
| Neutrophil Infiltration | 1 | 2012 | 201 | 0.12 | Why? |
| Leukocytes | 1 | 2019 | 1046 | 0.12 | Why? |
| Blood Coagulation | 3 | 2020 | 2768 | 0.11 | Why? |
| Heart-Assist Devices | 1 | 2020 | 812 | 0.11 | Why? |
| Resuscitation | 1 | 2017 | 638 | 0.11 | Why? |
| Animals | 9 | 2019 | 78931 | 0.11 | Why? |
| Aspirin | 1 | 2019 | 1043 | 0.11 | Why? |
| Serotonin Uptake Inhibitors | 1 | 2012 | 149 | 0.11 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.11 | Why? |
| Leukocytosis | 1 | 2012 | 280 | 0.11 | Why? |
| Heart Arrest | 2 | 2019 | 1239 | 0.11 | Why? |
| Chemotaxis, Leukocyte | 1 | 2010 | 82 | 0.11 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.11 | Why? |
| Mice, Inbred C57BL | 4 | 2018 | 5542 | 0.10 | Why? |
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 49 | 0.10 | Why? |
| Biomarkers | 8 | 2021 | 23361 | 0.10 | Why? |
| Inflammation Mediators | 2 | 2019 | 2654 | 0.10 | Why? |
| Muscle, Skeletal | 1 | 2017 | 915 | 0.10 | Why? |
| Receptors, Serotonin | 1 | 2009 | 16 | 0.10 | Why? |
| Registries | 8 | 2021 | 12327 | 0.10 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.10 | Why? |
| Middle Aged | 25 | 2021 | 270681 | 0.10 | Why? |
| Hypertension | 2 | 2021 | 8895 | 0.10 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.10 | Why? |
| Flow Cytometry | 2 | 2020 | 2393 | 0.10 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 5277 | 0.09 | Why? |
| Time Factors | 7 | 2021 | 31397 | 0.09 | Why? |
| Integrins | 1 | 2010 | 158 | 0.09 | Why? |
| Female | 30 | 2021 | 380317 | 0.09 | Why? |
| Refugees | 1 | 2018 | 809 | 0.09 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.09 | Why? |
| Renin-Angiotensin System | 2 | 2021 | 3661 | 0.09 | Why? |
| Endothelial Cells | 1 | 2019 | 2048 | 0.09 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 800 | 0.09 | Why? |
| Lung | 4 | 2020 | 31049 | 0.09 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 11367 | 0.09 | Why? |
| Prospective Studies | 11 | 2021 | 43301 | 0.09 | Why? |
| Lipopolysaccharides | 1 | 2012 | 848 | 0.09 | Why? |
| Oxidative Stress | 1 | 2019 | 2050 | 0.09 | Why? |
| Aged | 20 | 2021 | 215776 | 0.09 | Why? |
| Ventilators, Mechanical | 1 | 2020 | 2193 | 0.09 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2021 | 3892 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.09 | Why? |
| Acute Disease | 3 | 2017 | 6029 | 0.08 | Why? |
| Ultrasonography | 2 | 2020 | 4409 | 0.08 | Why? |
| Occupational Stress | 1 | 2021 | 2044 | 0.08 | Why? |
| Health Care Rationing | 1 | 2021 | 2558 | 0.08 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.07 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.07 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.07 | Why? |
| Venous Thrombosis | 1 | 2020 | 2739 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.07 | Why? |
| Oxygen | 1 | 2018 | 3715 | 0.07 | Why? |
| Cardiopulmonary Resuscitation | 1 | 2018 | 1876 | 0.07 | Why? |
| Disease Models, Animal | 2 | 2019 | 10998 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.07 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.07 | Why? |
| Adult | 12 | 2021 | 244371 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| Multicenter Studies as Topic | 2 | 2021 | 2437 | 0.06 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.06 | Why? |
| Kaplan-Meier Estimate | 1 | 2012 | 4260 | 0.06 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.06 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.06 | Why? |
| Critical Care | 3 | 2021 | 14081 | 0.06 | Why? |
| Shock, Septic | 1 | 2012 | 1313 | 0.06 | Why? |
| Hypoxia | 1 | 2017 | 3626 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.06 | Why? |
| Triage | 1 | 2021 | 7151 | 0.06 | Why? |
| Mice | 4 | 2017 | 21357 | 0.06 | Why? |
| Endothelium, Vascular | 1 | 2012 | 1751 | 0.06 | Why? |
| Respiration, Artificial | 3 | 2021 | 22116 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Decision Making, Organizational | 1 | 2021 | 104 | 0.05 | Why? |
| Sympathomimetics | 1 | 2019 | 22 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Survival Analysis | 3 | 2018 | 7592 | 0.05 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.05 | Why? |
| Critical Care Outcomes | 1 | 2020 | 138 | 0.05 | Why? |
| Comparative Effectiveness Research | 1 | 2020 | 178 | 0.05 | Why? |
| HLA-B Antigens | 1 | 2020 | 166 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2018 | 18 | 0.05 | Why? |
| Moral Obligations | 1 | 2021 | 125 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2018 | 72 | 0.05 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.05 | Why? |
| Purinergic P2Y Receptor Antagonists | 1 | 2020 | 206 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Phrenic Nerve | 1 | 2017 | 37 | 0.04 | Why? |
| Calcium Signaling | 1 | 2018 | 133 | 0.04 | Why? |
| Apolipoprotein A-I | 1 | 2018 | 148 | 0.04 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2021 | 15421 | 0.04 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.04 | Why? |
| Blood Pressure Determination | 1 | 2021 | 450 | 0.04 | Why? |
| Heart Failure | 1 | 2018 | 6638 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2018 | 673 | 0.04 | Why? |
| Risk Adjustment | 1 | 2021 | 730 | 0.04 | Why? |
| Allied Health Personnel | 1 | 2021 | 416 | 0.04 | Why? |
| Rest | 1 | 2017 | 188 | 0.04 | Why? |
| Sample Size | 1 | 2018 | 518 | 0.04 | Why? |
| Cardiac Output | 1 | 2017 | 183 | 0.04 | Why? |
| Multimodal Imaging | 1 | 2020 | 534 | 0.04 | Why? |
| Survival Rate | 2 | 2021 | 9206 | 0.04 | Why? |
| Coma | 1 | 2018 | 204 | 0.04 | Why? |
| Complement C3 | 1 | 2018 | 271 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Pedigree | 1 | 2017 | 502 | 0.04 | Why? |
| Arterial Pressure | 1 | 2017 | 208 | 0.04 | Why? |
| Withholding Treatment | 1 | 2021 | 798 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Organ Dysfunction Scores | 1 | 2021 | 1475 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2020 | 1444 | 0.03 | Why? |
| Cholesterol | 1 | 2018 | 660 | 0.03 | Why? |
| Placebos | 1 | 2017 | 629 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Standard of Care | 1 | 2021 | 1297 | 0.03 | Why? |
| Intersectoral Collaboration | 1 | 2021 | 1065 | 0.03 | Why? |
| Reference Standards | 1 | 2017 | 1163 | 0.03 | Why? |
| Advisory Committees | 1 | 2021 | 1418 | 0.03 | Why? |
| Single-Blind Method | 1 | 2017 | 1283 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2018 | 1262 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Drug Monitoring | 1 | 2020 | 1408 | 0.03 | Why? |
| Complement Activation | 1 | 2018 | 949 | 0.03 | Why? |
| Exercise Test | 1 | 2018 | 911 | 0.03 | Why? |
| rap1 GTP-Binding Proteins | 1 | 2010 | 5 | 0.03 | Why? |
| Electrocardiography | 2 | 2017 | 3957 | 0.03 | Why? |
| Contrast Media | 1 | 2017 | 1011 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Leukotriene B4 | 1 | 2010 | 46 | 0.03 | Why? |
| Actins | 1 | 2010 | 108 | 0.03 | Why? |
| Cell Polarity | 1 | 2010 | 85 | 0.03 | Why? |
| Cytoskeleton | 1 | 2010 | 99 | 0.03 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.03 | Why? |
| Host-Pathogen Interactions | 2 | 2020 | 11041 | 0.02 | Why? |
| Troponin I | 1 | 2018 | 1298 | 0.02 | Why? |
| Recovery of Function | 1 | 2020 | 2461 | 0.02 | Why? |
| Convalescence | 1 | 2020 | 2829 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2020 | 2262 | 0.02 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.02 | Why? |
| Coronary Angiography | 1 | 2018 | 2275 | 0.02 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 1458 | 0.02 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Out-of-Hospital Cardiac Arrest | 1 | 2017 | 1047 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Health Services Needs and Demand | 1 | 2021 | 3419 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Myocardium | 1 | 2017 | 2323 | 0.02 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Burnout, Professional | 1 | 2021 | 2489 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.02 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Occupational Exposure | 1 | 2021 | 4742 | 0.02 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Serine Endopeptidases | 1 | 2017 | 4606 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Health Policy | 1 | 2021 | 6242 | 0.01 | Why? |
| Fever | 1 | 2017 | 7795 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.01 | Why? |
| Hospital Mortality | 1 | 2019 | 22087 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |